A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose and Food-effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics of AMG 378 in Healthy Participants
Latest Information Update: 17 Jun 2025
At a glance
- Drugs AMG 378 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Amgen
Most Recent Events
- 10 Jun 2025 Planned End Date changed from 20 Sep 2028 to 4 Oct 2028.
- 10 Jun 2025 Planned primary completion date changed from 20 Sep 2028 to 4 Oct 2028.
- 17 Apr 2025 Planned End Date changed from 25 Sep 2028 to 20 Sep 2028.